← Browse by Condition

Medical Condition

glioblastoma

Total Trials

25

Recruiting Now

25

Trial Phases

Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for glioblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — glioblastoma Clinical Trials

How many clinical trials are currently recruiting for glioblastoma?

ClinicalMetric currently tracks 25 actively recruiting clinical trials for glioblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 25. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for glioblastoma?

glioblastoma research spans Phase 1 (11 trials), Phase 2 (5 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a glioblastoma clinical trial?

Eligibility criteria for glioblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

11

Phase 2

5

Phase 3

2

Top Sponsors

Beijing Biotech 2 trials

Johann Wolfgang Goethe University Hospital 1 trial

Hideho Okada, MD, PhD 1 trial

Dartmouth-Hitchcock Medical Center 1 trial

First Affiliated Hospital, Sun Yat-Sen University 1 trial

Recruiting Clinical Trials

NCT03383978 Phase 1

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Johann Wolfgang Goethe Univers...

NCT06186401 Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Hideho Okada, MD, PhD

Evaluation of the CONVIVO System

Dartmouth-Hitchcock Medical Ce...

Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients

First Affiliated Hospital, Sun...

NCT07541781 Phase 1

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Kailin Yang, MD, PhD

NCT05917145 Phase 1

ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma

NCT07141732 Phase 1

Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy

Joint Stock Company European M...

NCT06492486 Phase 2

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Tata Memorial Centre

NCT06496971 Phase 3

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NaviFUS Corporation

Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma

Institut Claudius Regaud

NCT06936046 Phase 2

Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression

Second Affiliated Hospital, Zh...

NCT06058988 Phase 2

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Memorial Sloan Kettering Cance...

NCT07480941 Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Beijing Biotech

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Hospices Civils de Lyon

NCT06991101 Phase 2

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Baptist Health South Florida

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Istituto Oncologico Veneto IRC...

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

University of Maryland, Baltim...

NCT07551336 Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Beijing Biotech

NCT04678648 Phase 1

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

RasCal Therapeutics, Inc.

NCT07493447 EARLY_Phase 1

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07093814 Phase 1, Phase 2

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Guangzhou Virotech Pharmaceuti...

NCT05902169 Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

United States, Austr...

Targeted Pediatric High-Grade Glioma Therapy

United States, Austr...

Nationwide Children's Hospital

NCT06072586 EARLY_Phase 1

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

St. Joseph's Hospital and Medi...

Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors

Union Hospital, Tongji Medical...

Related Conditions

recurrent glioblastoma (6) glioma (3) glioblastoma multiforme (3) brain cancer (3) high grade glioma (3) lung cancer (3) pancreatic cancer (3) mgmt unmethylated glioblastoma (2) meningioma (2) glioblastoma multiforme adult (2) brain tumor (2) malignant glioma (2)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology